cas 885702-34-1|| where to buy 4-bromo-2-chloropyrimidine

Produktname:4-bromo-2-chloropyrimidine

IUPAC Name:4-bromo-2-chloropyrimidine

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM124232-5g	in stock	ƐȅȖ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 885702-34-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:885702-34-1; Molekulare Formel:C4H2BrClN2; Schmelzpunkt:-; SMILES-Code:ClC1=NC=CC(Br)=N1; Dichte:

: Katalognummer:CM124232; Molekulargewicht:193.43; Siedepunkt:291.552°C at 760 mmHg; Mdl-Nr.:MFCD08272196; Lagerung:Keep in inert atmosphere, store in freezer, under -20°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Encorafenib plus Binimetinib; U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.